Tasos Konidaris - Mar 1, 2022 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Meredith Cook, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/3/2022, 08:19 PM
Previous filing: Nov 9, 2021
Next filing: Mar 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+36.2K	+41.26%		124K	Mar 1, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-36.2K	-25%	$0.00	109K	Mar 1, 2022	Class A Common Stock	36.2K		Direct	F2, F3
transaction	AMRX	Restricted Stock Units	Award	$0	+181K		$0.00	181K	Mar 3, 2022	Class A Common Stock	181K		Direct	F2, F4
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+362K		$0.00	362K	Mar 3, 2022	Class A Common Stock	362K		Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F4	The restricted stock units vest in four equal annual installments beginning on March 3, 2023.
F5	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F6	Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.